Cheminpharma-Allomek: A Modern Business Model for Funding Preclinical R&D
Connecticut Synthetic Chemistry Start-Up Developing Drugs
The Office of the Vice President for Research is pleased to share an opportunity to network with industry and scientists at an event sponsored by the BioscienceClubhouseCT, CURE – The Bioscience Network of CT, and featuring a graduate of UConn’s technology business incubator.
Join us at this Clubhouse event to hear Uday Khire, Founder and CEO of Cheminpharma LLC and Co-Founder of Allomek Therapeutics, share his experience managing two very different bio/pharma business operations, establishing funding for R&D, and his vision for the businesses. This will be an excellent opportunity for networking with the CT Bioscience Community.
Cheminpharma LLC, a chemistry services company, applies a non-traditional business model of using revenues generated from their business to fund novel preclinical candidates, for example they have developed a novel compound which is showing promise in cardiomyopathy and a variety of cancers. Allomek Therapeutics, a spin-off company from Cheminpharma was established to focus on developing the above mentioned compound. Allomek has received pre-seed funding from Connecticut Innovations and was also awarded Phase I STTR in collaboration with Columbia University. Both Cheminpharma and Allomek were nominated to be a recipient for the “Most Promising Life Science Product” by CT Technology Council.
Location: The Grove - 760 Chapel Street, New Haven, CT 06510, USA (location unchanged)
Notice New Date! Wednesday, Sept. 24th
Time: 4:00 pm – 5:30 pm
New registration link: http://www.eventbrite.com/e/cheminpharma-allomek-a-modern-business-model-for-funding-preclinical-rd-tickets-12531854113
Submitted by: Technology Acceleration Partners, Office of the Vice President for Research
For any further information, including car pool to the event, please contact Ana Fidantsef at fidantsef@uchc.edu
For more information, contact: Ana Fidantsef at fidantsef@uchc.edu